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IMPORTANCE Insomnia, hypersomnia, and an evening chronotype are common in individuals
with bipolar disorder (BD), but whether this reflects shared genetic liability is unclear.
Stratifying by BD subtypes could elucidate this association and inform sleep and BD research.
OBJECTIVE To assess whether polygenic risk scores (PRSs) for sleep traits are associated with
BD subtypes I and II.
DESIGN, SETTING, AND PARTICIPANTS This case-control studywas conducted in the United
Kingdom and Sweden with participants with BD and control participants. Multinomial
regression was used to assess whether PRSs for insomnia, daytime sleepiness, sleep duration,
and chronotype are associated with BD subtypes compared with control participants.
Affected individuals were recruited from the Bipolar Disorder Research Network. Control
participants were recruited from the 1958 British Birth Cohort and the UK Blood Service.
Analyses were repeated in an independent Swedish sample from August 2018 to July 2019.
All participants were of European ancestry.
EXPOSURES Standardized PRSs derived using alleles from genome-wide association studies
of insomnia, sleep duration, daytime sleepiness, and chronotype. These were adjusted for
the first 10 population principal components, genotyping platforms, and sex.
MAIN OUTCOMES ANDMEASURES Association of PRSs with BD subtypes, determined by
semistructured psychiatric interview and case notes.
RESULTS Themain analysis included 4672 participants with BD (3132 female participants
[67.0%]; 3404with BD-I [72.9%]) and 5714 control participants (2812 female participants
[49.2%]). Insomnia PRS was associated with increased risk of BD-II (relative risk [RR],
1.14 [95% CI, 1.07-1.21]; P = 8.26 × 10−5) but not BD-I (RR, 0.98 [95% CI, 0.94-1.03]; P = .409)
relative to control participants. Sleep-duration PRS was associated with BD-I (RR, 1.10 [95%
CI, 1.06-1.15]; P = 1.13 × 10−5) but not BD-II (RR, 0.99 [95% CI, 0.93-1.06]; P = .818).
Associations between (1) insomnia PRS and BD-II and (2) sleep-duration PRS and BD-I were
replicated in the Swedish sample of 4366 individuals with BD (2697 female participants
[61.8%]; 2627 with BD-I [60.2%]) and 6091 control participants (3767 female participants
[61.8%]). Chronotype and daytime-sleepiness PRS were not associated with BD subtypes.
CONCLUSIONS AND RELEVANCE Per this analysis, BD subtypes differ in genetic liability to
insomnia and hypersomnia, providing further evidence that the distinction between BD-I and
BD-II has genetic validity. This distinction will be crucial in selecting participants for future
research on the role of sleep disturbance in BD.
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B ipolar disorder (BD) and sleep have often been linked.First, reduced sleepduration, a symptomofmanic epi-sodes, has been implicated as a prodrome and trigger
ofmania.1-5 Second, insomnia (difficulty initiating andmain-
taining sleep6) andhypersomnia (prolonged sleepdurationor
excessivedaytime sleepiness7) are commonly reported symp-
toms of bipolar depression7-9 that persist in the interepisode
period9-18 and are associated with significant distress and
impairment.10 Third, there is evidence that individuals with
BD display greater evening preference for sleep (ie, an eve-
ningchronotype) thanhealthycontrolparticipants.19-21Atpre-
sent, sleep interventions for individuals with BD primarily
focus on reducing insomnia22-24 and stabilizing circadian
rhythms.25Understanding the association between sleep and
BD is important and could inform clinical interventions.
Recent genome-wide association studies (GWAS)26-31 pro-
vide anopportunity to examine the associationbetween sleep
andBDat the genomic level. Using summary-level data, some
studies have demonstrated a positive genetic correlation be-
tweenBDandsleepduration.28,30Otherstudies,however,have
found no significant genetic correlations between BD, chro-
notype,andinsomnia.26,28Theseanalyseshaveusedsummary-
level data and therefore may have been limited by a lack of
individual bipolar phenotypic and genotypic data. In particu-
lar, associations between BD subtypes6 (ie, type 1 [BD-I] and
type 2 [BD-II]) and sleep traits have been neglected, despite
evidence of heterogeneity between BD subtypes in genetics,
illnesscourse, clinical features, andetiologies.32-36There isalso
evidence that individualswith BD subtypes differ in sensitiv-
ity to sleep loss3 and rates of hypersomnia and insomnia dur-
ing depressive episodes.37
We therefore aimed to determine whether genetic liabil-
ity for insomnia, hypersomnia, and chronotypediffers inBD-I
andBD-II.Givena lackofevidenceonwhether thesesleeptraits
differ between individuals with BD-I or BD-II in the interepi-
sode period, we had no prior hypothesis about which sleep
traits, if any, would be associated with BD subtypes.
To test the associations between sleep and BD pheno-
types,weadopted thepolygenic risk score (PRS)method toes-
timate the burden of risk alleles associated with 4 sleep-
associated phenotypes (insomnia, sleep duration, excessive
daytime sleepiness, and chronotype) in people with BD-I or
BD-II and control participants.38,39 In secondary analyses,we
conducted a 2-sample mendelian randomization (MR) study
to test whether the data were consistent with a causal asso-
ciation between sleep and BD phenotypes.
Method
Sample Recruitment
IndividualsWith BD
Participants with BD were recruited within the United King-
dom by the Bipolar Disorder Research Network (bdrn.org).35
All participants reported their race as white, were genetically
unrelated, were 18 years or older, and had been recruited
systematically (eg, via community mental health teams) or
nonsystematically (eg, viawebsites, radio advertisements, or
voluntary groups, such as Bipolar UK). Participants were
excluded if they had affective illness experienced solely in
response to alcohol or substance misuse or secondary to
medical illness or medication use.
Participantsprovidedwritten informedconsent.Thestudy
had ethical approval from the West Midlands Multi-Centre
Research Ethics Committee, in addition to local research and
development approval by UK National Health Service Trusts
and Health Boards.
Control Participants
Control participants aged 18 years or older were recruited via
the UK Blood Service and the 1958 Birth Cohort. Characteris-
tics and recruitment of this sample has been described
previously.40 All control participants reported their race as
white.
Measures
Individuals with BD were assessed using the Schedules for
Clinical Assessment in Neuropsychiatry interview,41 admin-
istered by trained research psychologists or psychiatrists in
the research team (A.D.F., L.F., K.G.-S., L.J., N.C., and I.J.).
Information from this interview was combined with clinical
case note data to make lifetime best-estimate DSM-IV diag-
noses. Measures taken to increase reliability of distinguish-
ing BD subtypes are outlined in eAppendix 1 in the Supple-
ment. Interrater reliability for differentiating between a
best-estimate lifetime DSM-IV diagnosis of BD-I and BD-II
was found to be good (κ, 0.85).
Discovery Data Sets for Sleep Traits
The discovery data sets were GWAS summary statistics for
insomnia,27 sleep duration,30 daytime sleepiness,31 and
chronotype42 conducted in participants recruited to the UK
Biobank.43 Sleep phenotypes were assessed using touch-
screen questions. To assess insomnia symptoms, partici-
pantswere asked, “Doyouhave trouble falling asleep atnight,
or do you wake up in the middle of the night?” with the pos-
sible responses “never/rarely,” “sometimes,” “usually,” and
“prefer not to answer.” The insomniaGWASwas conducted in
236 163 participants who answered “usually” (affected indi-
viduals) or “never/rarely” (control participants). We chose to
Key Points
Question Does genetic liability to insomnia, hypersomnia, and
chronotype differentiate subtypes of bipolar disorder?
Findings In this case-control study of 4672 participants with
bipolar disorder and 5714 control participants, individuals with
bipolar disorder I had significantly greater genetic liability to longer
sleep duration, whereas individuals with bipolar disorder II had
significantly greater genetic liability to insomnia; these findings
were replicated in an independent sample. Individuals with bipolar
subtypes did not differ in genetic liability to morning or evening
chronotype.
Meaning Associations between polygenic liability to insomnia and
hypersomnia and clinical strata within bipolar disorder are shown
in this study for the first time, to our knowledge.
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use this relatively extreme GWAS rather than a larger GWAS
conducted by the same authors (ie, comparing responses of
never or rarelywith sometimes or usually for the question on
insomnia symptoms) because (1) we considered this to better
approximate meaningful insomnia; (2) it identified a larger
number of genome-wide significant loci (28 vs 9 in the larger
GWAS), suggesting that, despite the smaller sample size, a
clearer distinction in phenotype offered better power; and
(3) the authors used results of the extremes GWAS, not the
largerGWAS, invalidationanalyses. The sleep-durationGWAS
wasconducted in448609participantswhowereasked,“About
how many hours sleep do you get in every 24 hours? (Please
includenaps.)”Responseswere in 1-hour incrementsandwere
analyzed as a continuous variable. The daytime sleepiness
GWAS was conducted in 452071 participants and assessed
using thequestion, “Howlikelyareyoutodozeoffor fall asleep
during thedaytimewhenyoudon’tmean to? (eg,whenwork-
ing, reading,ordriving),”withresponses“never/rarely,”“some-
times,” “often,” or “all the time” analyzed on a scale of 1 to
4 points.
The chronotype GWAS consisted of 403 195 individuals
who answered the question “Do you consider yourself to
be….?” Those who answered “definitely a ‘morning’ person”
or “more a ‘morning’ than ‘evening’ person” were coded
as affected individuals, and those who answered “more
an ‘evening’ than a ‘morning’ person” or “definitely an
‘evening’ person” coded as control participants. Hence posi-
tive effect sizes from this GWAS indicate a morning chrono-
type, whereas negative effect sizes indicate an evening
chronotype.
Polygenic Risk Scores
Full details ongenotyping, quality control, and imputationare
in eAppendix 1 and the eFigure in the Supplement.We gener-
ated polygenic risk scores (PRSs) using PLINK version 1.944
in PRSice.45 Imputed genotypes were clumped for linkage
disequilibrium (window, 500 kb; r2 = 0.20), and single-
nucleotidepolymorphismsmost significantly associatedwith
sleep traits were retained. Clumping resulted in retaining
92 085, 92 096, and 91 950 single-nucleotide polymor-
phisms for daytime sleepiness, sleep duration, and insom-
nia, respectively.After clumping,PRSs for sleep traitsweregen-
erated using PRSice45 at P value thresholds (PT) P < 1.00,
P ≤ .50,P ≤ .20,P ≤ .10,P ≤ .05,P ≤ .01, andP ≤ .001 and con-
verted to z scores. This range of P value thresholds was cho-
sen in the absence of an independent sample that indicated
which PRS P value threshold explained the most variance in
each of the respective sleep phenotypes.
Statistical Analysis
Data analysis was conducted in R version 3.33 (R Foundation
for Statistical Computing). We performed multinomial logis-
tic regression analyses examining associations between PRS
for the aforementioned sleep traits (at the range of P value
thresholdsdescribed) and individualswithBDsubtypes (BD-I
orBD-II) vs control participants.All analyseswere adjusted for
sex and 10 population principal components. In sensitivity
analyses, we performed direct comparisons between the BD
subtype groups by first performing the samemultinomial re-
gressions but changing the reference group from control par-
ticipants to participantswith BD-I or BD-II, and then by using
logistic regressions that corrected for age, sex, and 10 popu-
lationprincipal components.Resultsare reportedat thePvalue
thresholds thatshowedthemostsignificant resultswitha false-
discovery rate correction applied (using the Benjamini and
Hochberg46 approach).
MRAnalyses
In cases in which we observed significant associations be-
tween sleep phenotype PRS and BD subtypes, we conducted
follow-up 2-sample MR studies to test whether sleep pheno-
types (exposures)were potentially causally related toBD sub-
types (the outcome).Mendelian randomization is a causal in-
ference method that uses genetic variants as instrumental
variables for an exposure of interest. It relies on 3 assump-
tions: (1) genetic variants must be strongly associated with
the exposure, (2) genetic variants should not be associated
with confounders of the exposure-outcome relationship, and
(3) genetic variants should only be associated with the out-
come through the exposure in question.47 We used genome-
wide significant single-nucleotide polymorphisms as genetic
instruments for the sleep phenotypes. Instrument-exposure
effects were taken from the sleep-trait GWAS summary sta-
tistics, and instrument-outcomeeffectswere taken fromBD-I
andBD-IIGWASsummary statistics.48FourMRmethodswere
used toassess relationshipsbetweensleepphenotypesandBD
subtypes: the inversevarianceweighted,49weightedmedian,50
weightedmode,51 andMREgger49 regressionmethods.To test
for evidence of pleiotropy, we examined the intercept of
MR Egger regressions49 and the Cochran Q and Rücker Q
statistics.52,53Datapruning,harmonization, andanalyseswere
conducted in R version 3.33 using the “TwoSampleMR”
package.54
Replication Sample
We sought to replicate the study findings using Swedish
individuals with BD (n = 4366) and control participants
(n = 6091) recruited via the StGöranBipolar project55 and the
SwedishNationalQualityRegister for Bipolar AffectiveDisor-
der (BipoläR).56,57 Full details of the samples, genotyping,
quality control, and imputation are in eAppendix 2 in the
Supplement.
Results
Sample Description
Among the individuals with BD, 3132 were female (67.0%),
with a median age of 46 (range, 18-89) years. A total of 3404
participants met criteria for BD-I, and 1268 met criteria for
BD-II. Among control participants, 2812 of 5714 (49.2%)
were female. The Swedish sample consisted of 6091 control
participants (3767 female participants [61.8%]) and 4366
affected individuals (2697 female participants [61.8%]),
of whom 2627 met criteria for BD-I and 1739 met criteria
for BD-II.
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Correlations Between PRSs for Sleep Traits
Across all PRS P value thresholds, insomnia PRSs were nega-
tively associated with sleep-duration PRSs (r range, −0.17 to
−0.30; P < 1 × 10−4) and positively associated with daytime-
sleepiness PRSs (r range, 0.04-0.10; P = .007 to P < 1 × 10−4).
Sleep-duration PRSs were negatively associated with
daytime-sleepiness PRSs (r range, −0.03 to −0.00), but these
associations were not significant across all thresholds
(range, P = .028-.916). Morningness PRSs were not signifi-
cantly associated with PRS for insomnia, sleep duration, or
daytime sleepiness.
PRSs for Sleep Traits: Case-Control Analyses
Logistic regression comparing individuals with BD with con-
trol participants revealed that, across all PRS P value thresh-
olds, case status was significantly associated with PRSs for
sleep duration (odds ratio [OR], 1.07 [95% CI, 1.03-1.12];
P = 5.52 × 10−4; P = 5.52 × 10−4 with adjustment for false-
discovery rate [PRSPT < 1.00])anddaytimesleepiness (OR, 1.10
[95%CI, 1.06-1.15];P = 2.31 × 10−6;P = 1.05 × 10−5withadjust-
ment for false-discovery rate [PRS PT ≤ .01]) and negatively
associatedwithmorning chronotype (OR, 0.91 [95%CI, 0.88-
0.95];P = 1.86 × 10−5;P = 6.26 × 10−5withadjustment for false-
discovery rate [PRS PT ≤ .05]) but not significantly associated
with insomnia (OR, 0.98 [95% CI, 0.94-1.02]; P = .39 [PRS
PT < 1.00]; eTables 2-5 in the Supplement).
PRS for Sleep Traits by BD Subtypes
Results at the most significant PRS P value thresholds (with
corrected P values) are summarized. Results at other PRS
P value thresholds (PT) are provided in eAppendix 1 and
eTables 18 and 19 in the Supplement.
Insomnia PRS
Multinomial regressions comparing individuals with BD sub-
types to control participants revealed that insomnia PRS was
significantly associatedwith a decreased risk of BD-I at a PRS
PTofP < 1.00andP ≤ .50,but significant associationswerenot
seen at other P value thresholds (eTable 6 in the Supple-
ment). At all P value thresholds, insomnia PRS was signifi-
cantly associated with BD-II (relative risk [RR], 1.14 [95% CI,
1.07-1.21]; P = 8.26 × 10−5, P = .001 with false-discovery rate
adjustment [PRSPT ≤ .001]). Results at allPT are shown in the
Figure, A. In direct tests, insomnia PRS was significantly as-
sociatedwithBD-II comparedwithBD-I (RR, 1.16 [95%CI, 1.08-
1.24];P = 1.39 × 10−5;P = 1.95 × 10−4with false-discovery rate
Figure. Relative Risk Ratios for IndividualsWith Bipolar Subtypes vs Control Participants
1.3
1.1
1.0
0.9
0.8
InsomniaA
1.3
1.1
1.0
0.9
0.8
Daytime sleepinessC
1.2
1.2
Re
la
tiv
e 
Ri
sk
Individuals
With Bipolar I
Individuals
With Bipolar II
1.3
1.1
1.0
0.9
0.8
Re
la
tiv
e 
Ri
sk
Sleep durationB
Individuals
With Bipolar I
Individuals
With Bipolar II
Re
la
tiv
e 
Ri
sk
Individuals
With Bipolar I
Individuals
With Bipolar II
1.3
1.1
1.0
0.9
0.8
Re
la
tiv
e 
Ri
sk
MorningnessD
1.2
1.2
Individuals
With Bipolar I
Individuals
With Bipolar II
.001 .01 .05 .10 .20 .50 1.00
Polygenic risk score P value threshold
Relative risk of insomnia (A), sleep duration (B), daytime sleepiness (C), andmorningness (D) for patients with bipolar subtypes compared with control participants,
as anticipated based on polygenic risk scores. Error bars indicate 95% CIs.
Research Original Investigation Comparison of Genetic Liability for Sleep Traits in Individuals With Bipolar Disorder and Controls
E4 JAMAPsychiatry Published online November 21, 2019 (Reprinted) jamapsychiatry.com
Downloaded From: https://jamanetwork.com/ by a Cardiff University User  on 11/22/2019
adjustment; OR, 1.14 [95% CI, 1.07-1.22]; P = 6.81 × 10−5 [PRS
PT ≤ .001]; eTables 10-11 in the Supplement).
Sleep-Duration PRS
At all PRSPvalue thresholds,multinomial regression compar-
ing individuals with BD subtypes with control participants
revealed that sleep-duration PRS was associated with BD-I
(RR, 1.10 [95%CI, 1.06-1.15];P = 1.13 × 10−5;P = 1.07 × 10−4with
false-discovery rateadjustment [PRSPT < 1.00]; eTable7 in the
Supplement). Associations between sleep-duration PRS and
BD-IIwerenotsignificantatanyPRSPvalue threshold (eTable7
in theSupplement).Results at allPvalue thresholds are shown
in the Figure, B. Direct comparisons between the subgroups
with BD-I and BD-II revealed that sleep-duration PRS was
significantly associated with BD-I (RR, 1.11 [95% CI, 1.04-
1.19];P = 1.69 × 10−3;P = 4.74 × 10−3with false-discovery rate
adjustment; OR, 1.11 [95% CI, 1.04-1.19]; P = .002 [PRS
PT < 1.00]; eTables 12-13 in the Supplement).
Daytime-Sleepiness PRS
Comparedwith thecontrol group,daytime-sleepinessPRSwas
associated with BD-I and BD-II at all PRS P value thresholds
(except PT < .001; eTable 8 in the Supplement). Results at all
PRS PT are shown in the Figure, C. Direct comparisons be-
tween BD subtypes were not significant after correction for
multiple testing (eTable 14-15 in the Supplement).
Chronotype PRS
Polygenic risk score formorningnesswas associatedwith a re-
duced relative risk of BD-I in affected individuals compared
with the control participants (RR, 0.90 [95% CI, 0.86-0.95];
P = 1.06 × 10−5; P = 1.11 × 10−4 with false-discovery rate ad-
justment [PRS PT ≤ .50] at all PRS P value thresholds except
PT less than .001. In individuals with BD comparedwith con-
trol participants, morningness PRS was associated with a re-
duced risk of BD-II, but this findingwas not significant across
most PRSPvalue thresholds (eTable9 in theSupplement). Re-
sults at all PRSs are shown in the Figure. Direct comparisons
between BD subtypes were not significant (eTable 16-17 in
the Supplement).
MRAnalyses
Across all MR methods, we did not find evidence of a poten-
tial causal relationship between insomnia and BD-II or sleep
duration and BD-I. However, the direction of effect was con-
sistentwhenassessingtheeffectof insomniawithBD-II (Table).
Although MR Egger intercepts were not significantly differ-
ent from zero for analyses of BD-I and BD-II , the Cochran Q
and RückerQ statistics indicated significant heterogeneity in
effect estimates (insomnia:RückerQ35 = 53.33;P = .024;Coch-
ranQ36 = 54.03;P = .027; sleepduration:RückerQ54 = 126.92;
P = 8.33 × 10−8; Cochran Q55 = 128.91; P = 7.18 × 10−8; Table),
possibly because of horizontal pleiotropy.
Replication Sample
In the Swedish sample, insomnia PRS was significantly asso-
ciated with BD-II (RR, 1.07 [95% CI, 1.01-1.13]; P = .013 [PRS
PT ≤ .001]) compared with control participants, whereas the
associationwithBD-Iwas not significant. Sleep-durationPRS
wasassociatedwitha significant increased relative riskofBD-I
compared with control participants (RR, 1.11 [95% CI, 1.06-
1.16]; P = 1.72 × 10−5 [PRS PT < 1.00]). The association be-
tween sleep-duration PRS and BD-II was marginally signifi-
cant (RR, 1.06 [95% CI, 1.00-1.12]; P = .042 [PRS PT <1.00]).
Discussion
Bipolardisorder isheterogeneous insymptompresentationand
most likely in the mechanisms that underlie these presenta-
tions.Geneticscanhelprefinediagnosticgroupsthatsharesimi-
lar etiologies.58 In this study,we providewhat is to our knowl-
edge the first evidence that genetic liability to insomnia and
longer sleep duration differs according to BD subtype.
Genetic liability to insomnia as indexed by PRSwas asso-
ciated with increased relative risk of BD-II compared with
control participants and those with BD-I. The stronger asso-
ciation between insomnia PRS andBD-IImay explain nonsig-
nificant genetic correlations between BD and insomnia in
previous research,26,28 because individuals with BD-II are
usually underrepresented in BD GWAS (eg, only 11% in a re-
cent study59). Future research should explore possible rea-
sons for this association.
Hypersomnia in BD populations has remained relatively
underresearched, but researchers have recently called for in-
creased efforts to understand its underlying biology and role
in BD.16,60 This is because of its high prevalence and recur-
renceacrossbipolardepressive episodes7,37 in addition tohigh
Table. Results of 2-SampleMendelian Randomization Studies
Mendelian Randomization
Method
Insomnia in Bipolar Disorder IIa Sleep Duration in Bipolar Disorder Ib
log(Odds Ratio)
or Q Statistic SE or df P Value
log(Odds Ratio)
or Q Statistic SE or df P Value
Inverse variance weightedc 0.256 0.149 .087 0.396 0.209 .059
Weighted medianc 0.355 0.183 .052 0.245 0.219 .264
Weighted modec 0.410 0.300 .180 0.005 0.361 .990
MR Eggerc 0.577 0.498 .255 -0.274 0.757 .719
Rücker Qd 53.33 35 .024 126.92 54 8.33 × 10−8
Cochran Qd 54.03 36 .027 128.91 55 7.18 × 10−8
a 37 Single-nucleotide polymorphisms.
b 56 Single-nucleotide polymorphisms.
c Log(odds ratio) and SEs are presented.
dQ statistics and df are presented.
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interepisode prevalence and associationwith relapse.17,61We
usedsleep-durationanddaytime-sleepinessPRSasproxies for
genetic liability to hypersomnia. Sleep-duration PRS was as-
sociatedwith increased relative risk of BD-I but not BD-II and
wassignificantlymorestronglyassociatedwithBD-I thanBD-II
inadirectcomparison. Incontrast,daytime-sleepinessPRSwas
not significantly associated with BD subtypes. Daytime-
sleepiness PRS may be a proxy for insomnia, in that daytime
sleepiness canbe inducedby insomnia,62 andweobservedsig-
nificant positive correlations between insomnia anddaytime-
sleepiness PRS. These results support existing researchon the
importance of hypersomnia in individuals with BD16,60 (and
BD-I in particular37) andprovide further evidence that hyper-
somnia is not a unitary construct.63,64
The results of theMR analyses do not support potentially
causal relationships between insomnia andBD-II or sleep du-
ration and BD-I. However, we observed significant heteroge-
neity in the genetic instruments, thereby violating the third
assumption of MR and potentially biasing the results. There-
fore,while insomnia and sleep duration could be useful clini-
cal stratifiers, there is currently insufficient evidence to sup-
port a causal inference.Further research isneeded toelucidate
the biologicalmechanismsunderpinning the genetic associa-
tion between BD-I and longer sleep duration.
Implications
Clinical and biological heterogeneity, combinedwith a classi-
fication that is not grounded in biology, are obstacles to ad-
vancing BD research.We provide some evidence of heteroge-
neity in genetic propensity to some sleep traits within BD
(specifically insomnia and sleep duration), highlighting dif-
ferences in theway some sleep-associated genetic factors are
associated with BD subtypes. This adds to previously pub-
lishedworkon stratification inBD65 andwork suggesting that
different factors may influence the 2 conditions.32-34
These results suggest that clinical trials of sleep interven-
tions should stratify participants by clinical subtype and ge-
netic liability to insomniaorhypersomnia.Futureworkshould
explorewhich factors drive the differences in genetic liability
for insomnia/sleep duration between BD subtypes.
Strengths
This study was conducted on the world’s largest single co-
hort of BD with genotypic and phenotypic data. Phenotypic
data were collected using face-to-face semistructured inter-
views and case notes with high interrater reliability. Wewere
thereforeable toexploregenetic associationsusing individual-
level geneticdata,whichprovidedmoregranularity thansum-
mary statistics. In addition, we were able to replicate the re-
sults for insomnia PRS and BD-II and sleep-duration PRS and
BD-I in an independent sample.
Limitations
This study has several limitations. First, potential recruit-
ment bias in our BD sample may have reduced its representa-
tiveness and influenced the results.66 Second, we were
unable to adjust for additional variables (eg, age, education),
because these were unavailable for control participants.
Third, the index of hypersomnia is imprecise because the
available GWAS summary statistics measured sleep duration
as total hours slept30; previous work suggests that hypersom-
nia is better characterized by total time in bed.17,64,67 Fourth,
there is evidence that 5% to 17% of patients with BD-II con-
vert to BD-I,68,69 which could have resulted in some indi-
viduals with BD-II being misclassified in this sample. How-
ever, this would have reduced power to observe differences
between the 2 subtypes rather than resulted in positive
results we observe for insomnia and sleep duration. Finally,
variants associated with insomnia or hypersomnia at ages 40
to 69 years (the age of the UK Biobank sample43) may differ
from those associated in childhood or early adulthood. This
may have increased our type-2 error rate, because most
patients with BD experience the first onset of impairing
symptoms in adolescence or early adulthood.70 Genetic risk
for insomnia or hypersomnia that manifests during or prior
to early adulthood may be more strongly associated with BD
than those associated with midlife insomnia. These results
should be replicated using future sleep trait GWAS in younger
samples of sufficient size for PRS analysis.
Conclusions
To our knowledge, this is the first study to explore whether
genetic liability for sleep traits is associatedwith clinical strata
of individuals with BD. Futurework should explore potential
mechanisms underlying differences between the BD sub-
types in genetic liability for sleep traits.
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